mCRC
Oncology · 2013–2024
9decisions
6medicines
6carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| fruquintinib Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for… | Sep 2024 | Recommended with restriction | input received Bowel Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| cetuximab Treatment of metastatic colorectal cancer (mCRC) in RAS wild-type patients, including first-line treatment in combination with chemotherapy, second-line… | Mar 2024 | Recommended | input received Medical Oncology Group |
| regorafenib Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered suitable candidates for,… | Nov 2021 | Not recommended | input received Bowel Cancer Australia |
| trifluridine with tipiracil Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies… | Jul 2018 | Recommended | 1 individuals |
| trifluridine with tipiracil Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies… | Mar 2017 | Not recommended | unclear |
| trifluridine with tipiracil Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies… | Nov 2017 | Not recommended | input received |
| panitumumab Treatment of first-line and later-line metastatic colorectal cancer (mCRC) in patients with wild-type RAS tumours. | Jul 2014 | Recommended | none received |
| cetuximab First-line treatment in combination with chemotherapy (FOLFIRI) for patients with metastatic colorectal cancer (mCRC) whose tumours have RAS wild-type status. | Nov 2014 | Recommended with restriction | 2 individuals |
| aflibercept Treatment of metastatic colorectal cancer (mCRC) in combination with irinotecan-fluoropyrimidine-based chemotherapy in patients with previous treatment with an… | Jul 2013 | Recommended | no section in document |
Who spoke
Medical Oncology Group · Bowel Cancer Australia · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.